Perception of Affordances and Obstacle Crossing in People With Parkinson's Disease and Healthy Adults
NCT06932679, Recruiting, University of Haifa
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Perception of Affordances and Obstacle Crossing in People With Parkinson's Disease and Healthy Adults | ClinicalTrials.gov |
| NCT number | NCT06932679 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 180 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Haifa | ClinicalTrials.gov |
| Conditions | Parkinson's Disease (PD) | ClinicalTrials.gov |
| Interventions | Assessment of Gait and Visual Exploration | ClinicalTrials.gov |
| First posted | 2025-04-17 | ClinicalTrials.gov |
| Last updated | 2025-07-22 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Affordance Perception Accuracy | During single laboratory session (about 3 hours) | Accuracy of participants' perception of their ability to cross obstacles of varying height and surface conditions. Participants will judge whether they can safely cross an obstacle prior to walking. | ClinicalTrials.gov |
| Primary | Affordances measured by gaze behavior | During a single laboratory session (approximately 3 hours) | Eye movement patterns during obstacle approach and crossing. Gaze behavior will be recorded using wearable eye-tracking glasses (Tobii Pro Glasses 3) to assess visual exploration of the walking environment and obstacle. Measures will include fixation(on obstacle) duration (milisecondes). | ClinicalTrials.gov |
| Secondary | Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | During a single laboratory session (approximately 3 hours) | Disease severity will be assessed using the MDS-UPDRS (Motor Examination). This standardized clinical assessment measures motor symptoms in people with Parkinson's disease, including tremor, rigidity, bradykinesia, and postural stability. Higher scores indicate greater motor impairment. | ClinicalTrials.gov |
| Secondary | Walking Speed | During a single laboratory session (approximately 3 hours) | Walking speed during obstacle crossing tasks, measured using wearable sensors (APDM Mobility Lab). Walking speed will be calculated in meters per second based on time and distance walked during the trials. | ClinicalTrials.gov |
| Secondary | Step Length | During a single laboratory session (approximately 3 hours) | Step length during obstacle crossing tasks, measured using wearable sensors (APDM Mobility Lab). Step length will be calculated in meters for each leg during walking trials, as an indicator of gait characteristics and stability. | ClinicalTrials.gov |
| Secondary | Levodopa Equivalent Daily Dose (LEDD) | During a single laboratory session (approximately 3 hours) | The total daily dose of antiparkinsonian medications will be calculated for participants with Parkinson's disease using the standardized Levodopa Equivalent Daily Dose (LEDD) formula. Higher values indicate greater medication use. | ClinicalTrials.gov |
| Secondary | Cognitive Performance - Stroop Test (NeuroTrax Cognitive Battery) | During a single laboratory session (approximately 3 hours) | Cognitive function will be assessed using the computerized NeuroTrax Cognitive Battery. Specifically, performance on the Stroop test will be used to evaluate executive function, focusing on response inhibition and attention control. The Stroop test provides accuracy and reaction time scores, with higher scores reflecting better performance. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)